American Diabetes Association 80th Scientific Sessions

June 12-16, 2020; Virtual; Category Document – Notable Posters

Executive Highlights

  • This document lists the 50 posters that we’re most looking forward to at ADA 2020, including late-breakers. From the 2,000+ posters that ADA will make available virtually during this year’s conference, we’ve narrowed it down to 25 in diabetes therapy and 25 in diabetes tech that we’re especially excited to see.

  • Late-breaking posters in therapy include an analysis of time-in-range vs. MACE in the DEVOTE trial (from Dr. Rich Bergenstal), potential use cases for oral insulin (from Dr. Julio Rosenstock), and results from Simplici-T1 on a novel glucokinase activator for type 1 treatment (from Dr. John Buse). Several posters will feature new insulin data – on Novo Nordisk’s Fiasp (faster-acting aspart), Lilly’s ultra-rapid lispro, and MannKind’s inhalable Afrezza. We appreciate ADA’s focus on diabetes prevention as well as treatment, and to that end, look forward to a slate of posters on prediabetes intervention (a workplace digital DPP, a meta-analysis of RCTs comparing metformin with intensive lifestyle change, and a secondary analysis of the Da Qing Diabetes Prevention Outcomes Study).

  • Automated insulin delivery leads the way in diabetes tech posters, which will include real-world data from the first 30 days of Tandem’s Control-IQ (from Dr. Lars Mueller). In a separate poster (from Dr. Stephanie Habif), we’ll also see real-world Control-IQ data from both type 1 and type 2 users. We’ll also be taking a look at data from MiniMed 780G, Diabeloop, Beta Bionics’ iLet, and Insulet’s Omnipod Horizon. Abbott and Dexcom headline the CGM-related posters, building on the evidence base around CGM’s effectiveness in a variety of settings and populations. This year’s ADA also includes several promising policy-and-education-related posters around diabetes tech. Ones we’re most looking forward to include findings from the T1D Exchange’s Quality Improvement Collaborative on improving CGM and pump use and physician well-being around tech-use and clinical workflow.

The ADA offers an online itinerary planner that you can use to search for sessions and abstracts as well as organize your conference schedule. Each Abstract ID in this document has been hyperlinked to the session’s page on the itinerary planner to help you assemble your personal schedule.

Embargoed abstracts will go live on the ADA itinerary planner on Tuesday, June 9, 2020. Please note: while the abstracts are publicly available on the ADA itinerary planner (and linked to in our category documents), they are still under embargo until the ADA meeting. See the ADA embargo policy for specifics on when each individual embargo lifts.

For more recommendations on how to make the best use of our category documents, see our “What is a Category Document” tip sheet.

This was our first take at this document and we encourage readers to please be in touch with what we missed!

 

Diabetes Therapy

Abstract ID

Title

Authors

Categories

7-LB

Insulin and Glucagon Coadministration in Type 1 Diabetes Prevents Hypoglycemia without Worsening Hyperglycemia

Bruce Bode

Hypoglycemia

21-LB

Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial

Rich Bergenstal

Insulin, Diabetes Complications

26-LB

Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study

Xiangyu Wang

GLP-1, Diabetes Complications

59-LB

Risk of Type 2 Diabetes Is Reduced in the Second Year of a Digital Diabetes Prevention Program in a Workplace Setting

Charles Birse

Prediabetes

66-LB

Combined Immunotherapy with T Regulatory Cells and Anti-CD20 Antibody Prolongs Survival of Pancreatic Islets in Type 1 Diabetes

Piotr Trzonkowski

Type 1

93-LB

Preferences and Health State Utilities Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide

Kristina Boye

GLP-1

105-LB

Evening Oral Insulin (ORMD-0801) Glycemic Effects in Uncontrolled T2DM Patients

Julio Rosenstock

Insulin

112-LB

ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)

Grégory Meiffren

Novel Therapies, Type 1

115-LB

Oral Insulin–Induced Reduction in Liver Fat Content in T2DM Patients with Nonalcoholic Steatohepatitis

Miriam Kidron

Insulin, Diabetes Complications

121-LB

Durable Glycemic Improvements after Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (T2D): 48-Week Results from the REVITA-2 European Cohort

Geltrude Mingrone

Novel Therapies

122-LB

The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes

John Buse

Novel Therapies, Type 1

131-LB

Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

Silvio Inzucchi

SGLT-2

149-LB

Reluctant to Lose Control: Older Patients’ A1C Goals Lower than ADA Guidelines

Michael Cui

Policy & Education

379-P

Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes

Kasia Lipska

Diabetes Complications, Policy & Education

402-P

Comparison of the Effects of Sodium–Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes

Seung Eun Lee

SGLT-2, Diabetes Complications

490-P

Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial

Joseph Timmons

Diabetes Complications, Type 1

494-P

Effects of a Novel Xanthine Oxidase Inhibitor, TMX-049, on Urinary Albumin Excretion in Patients with Type 2 Diabetes and Albuminuria

George Bakris

Diabetes Complications, Novel Therapies

562-P

Influence of Glycemic Control and Variability on Diabetic Retinopathy in Type 1 Diabetes Patients on Continuous Subcutaneous Insulin Infusion Therapy

Edurne Lecumberri

Diabetes Complications

836-P

The Effect of Intensive Lifestyle Modification Compared with Metformin Interventions on Fasting Blood Glucose: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Michaela Kucab

Prediabetes

844-P

Effects of Dapagliflozin, Metformin, or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial

Kim Clemmensen

Prediabetes, SGLT-2

1018-P

Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)

Ronnie Aronson

Insulin

1024-P

Technosphere Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (Aspart) 70/30 Mixture in Type 2 DM

David Kendall

Insulin

1034-P

Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen

Wendy Lane

Insulin

1043-P

GoBolus Study: Impact of Faster Aspart on Glycemic Control in a Real-World Population with Type 1 Diabetes on Basal-Bolus Therapy as Multiple Daily Injections Using Flash Glucose Monitoring

Thomas Danne

Insulin

1471-P

Efficacy of Lifestyle Intervention in Preventing Diabetes in People with IGT with and without Impaired Fasting Glucose: A Secondary Analysis of Da Qing Diabetes Prevention Outcomes Study (DQDPOS)

Qiuhong Gong

Prediabetes

 

Diabetes Technology

Abstract ID

Title

Authors

Categories

14-LB

Overnight Hypoglycemia Prediction for CGM Users

Dan Goldner

CGM, Hypoglycemia

35-LB

Reliability of an Artificial Intelligence (AI) Diabetic Retinopathy (DR) Detection System

Eli Ipp

Diabetes Complications

67-LB

Clinical Cost Offset Analysis Comparing Real-Time CGM (RTCGM) with SMBG Based on the COMISAIR 3-Year Follow-Up Study

Christopher Parkin

CGM, Policy & Reimbursement

68-LB

Use of Real-Time CGM Is Associated with Fewer Hospitalizations Compared with SMBG in the Insulin-Treated Medicare Population

Christopher Parkin

CGM, Policy & Reimbursement

71-LB

Contour Next One Used with the Smartphone Application Contour Diabetes App Improved Self-Management and Adherence without Reducing Quality of Life in Patients with Diabetes

Diego Fernandez-Garcia

CGM, Digital Health

74-LB

Sustainable HbA1c Decrease at 12 Months for Adults with Type 1 and Type 2 Diabetes Using the FreeStyle Libre System: A Study within the National Diabetes Register in Sweden

Fleur Levrat-Guillen

CGM

77-LB

Improved A1C and TIR in Adults with T2D Participating in a CGM-Driven Virtual Diabetes Clinic

Amit Majithia

CGM

78-LB

HbA1c Reduction Associated with a FreeStyle Libre System in People with Type 2 Diabetes Not on Bolus Insulin Therapy

Eugene Wright

CGM

84-LB

HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy

Eden Miller

CGM

85-LB

Freestyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes without Bolus Insulin

Eden Miller

CGM

95-LB

Control-IQ Technology in the Real World: The First 30 Days

Lars Mueller

Insulin Delivery

96-LB

Diabeloop Closed-Loop System Allows Patients with Type 1 Diabetes (T1D) to Significantly Improve Their Glycemic Control in Real-Life Situation, without Serious Adverse Events: A 6-Month Follow-Up

Coralie Amadou

Insulin Delivery

97-LB

Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in Subjects with T1D

Anders Carlson

Insulin Delivery

98-LB

Individual Glycemic Response to Ultra-Rapid vs. Rapid Insulin Delivered Automatically with the Ilet Bionic Pancreas System

Jordan Sherwood

Insulin Delivery

100-LB

Closed-Loop Control Reduces Hypoglycemia without Increased Hyperglycemia in Subjects with Increased Prestudy Hypoglycemia: Results from the iDCL DCLP3 Randomized Trial

Carol Levy

Insulin Delivery

126-LB

Glycemic Outcomes for People with Type 1 and Type 2 Diabetes Using Control-IQ Technology: Real-World Data from Early Adopters

Stephanie Habif

Insulin Delivery

145-LB

Improving Continuous Glucose Monitoring (CGM) Use across Ten National Centers: Results from the T1D Exchange Quality Improvement Collaborative (T1DX-QI)

Osagie Ebekozien

CGM, Policy & Education

146-LB

Increasing Insulin Pump Use across Five National Diabetes Centers: Results from the T1D Exchange Quality Improvement Collaborative (T1DX-QI)

Osagie Ebekozien

Insulin Delivery, Policy & Education

153-LB

Physician Well-being Related to Diabetes Technology and Clinic Workflow

Vrushali Shah

Policy & Education

621-P

Digital Diabetes Education Program Improves Knowledge, Self-Efficacy, and Health Behaviors among People with Type 2 Diabetes

Zachary White

Digital Health, Policy & Education

677-P

Use of a Hybrid Closed-Loop System Lowers CHO Requirements during Prolonged Exercise

Michael Mueller-Korbsch

Insulin Delivery

852-P

Is Real-Time CGM Superior to Flash Glucose Monitoring? Results of the Type 1 Diabetes CORRIDA Randomized Control Trial

Jan Soupal

CGM

892-P

Comparison of Dexcom G6 CGM with Self-Monitoring Blood Glucose in Young Adults with Type 1 Diabetes: The Millennial Study

Hood Thabit

CGM

918-P

Effectiveness of Freestyle Libre Flash Glucose Monitoring System on the Diabetes Distress among Type 1 Diabetes: A Prospective Study

Mohammed Aldawish

CGM

1276-P

First Home Evaluation of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes

Bruce Buckingham

Insulin Delivery

 

 

--by Payal Marathe, Albert Cai, Martin Kurian, and Kelly Close